• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At IDEAYA Biosciences (IDYA) Valuation After UBS Highlight And Returned GSK Programs

    Simply Wall St·01/08/2026 19:38:37
    語音播報

    What sparked fresh interest in IDEAYA Biosciences?

    IDEAYA Biosciences (IDYA) has come into focus after UBS highlighted its clinical pipeline. The firm pointed in particular to darovasertib and the DLL3 antibody drug conjugate, and also noted GlaxoSmithKline returning the Werner Helicase and Pol Theta programs.

    See our latest analysis for IDEAYA Biosciences.

    Those UBS comments and the upcoming J.P. Morgan Healthcare Conference are landing at a time when IDEAYA’s share price has already seen a 41.32% 90 day share price return and a 52.35% 1 year total shareholder return. This points to building momentum around its pipeline story at a last close of $37.86.

    If this kind of biotech interest has your attention, it could be a good moment to widen the lens and look at healthcare stocks as potential next ideas.

    With IDEAYA’s shares already up strongly over 1 year, current revenue growth of 31.23% and an intrinsic discount flagging possible mispricing, investors may wonder whether there is still upside here or if the market is already baking in potential future success.

    Price-to-Sales of 15.4x: Is it justified?

    On a P/S of 15.4x at a last close of $37.86, IDEAYA looks expensive relative to peers, which suggests the market is pricing in a lot of future success.

    The P/S ratio compares the company’s market value to its current revenue, so for a biotech like IDEAYA, it effectively reflects what investors are willing to pay today for each dollar of current sales while they wait to see how the clinical pipeline plays out.

    According to the Simply Wall St checks, IDEAYA is described as expensive on a P/S basis versus both the peer average of 11.5x and the US Biotechs industry average of 11.7x. The estimated fair P/S ratio based on the SWS model is 1.8x, a far lower level the market could theoretically move toward if expectations cooled.

    Put differently, the current 15.4x P/S stands far above both the peer group and the modelled fair ratio. This points to a rich revenue multiple compared to what similar names and the regression based fair multiple suggest.

    Explore the SWS fair ratio for IDEAYA Biosciences

    Result: Price-to-Sales of 15.4x (OVERVALUED)

    However, the story can change quickly if clinical data disappoints or if partnerships with larger pharma groups evolve in ways the market does not expect.

    Find out about the key risks to this IDEAYA Biosciences narrative.

    Another angle on value: what does the DCF say?

    While the 15.4x P/S suggests a rich price for each dollar of current sales, our DCF model points in the opposite direction. At a last close of $37.86, IDEAYA is trading around 71% below the SWS DCF fair value estimate of $129.97. This raises an obvious question: is the market overpaying for revenue or underpricing long term cash flow potential?

    Look into how the SWS DCF model arrives at its fair value.

    IDYA Discounted Cash Flow as at Jan 2026
    IDYA Discounted Cash Flow as at Jan 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 882 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Build Your Own IDEAYA Biosciences Narrative

    If you look at these numbers and come to a different conclusion, or simply prefer to rely on your own work, you can build your version in just a few minutes, starting with Do it your way.

    A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Looking for more investment ideas?

    If IDEAYA has sparked your curiosity, do not stop here, the screener can help you spot other opportunities before they move out of reach.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.